Reckitt Benckiser falls after losing drug exclusivity - UPDATE

Shares in Reckitt Benckiser were hammered on Monday by the news that it has lost exclusivity over its SUBOXONE tablets after the Food and Drug Administration (FDA) gave two drug manufacturers the green light to produce generic versions of the drug.

Shares in Reckitt Benckiser were hammered on Monday by the news that it has lost exclusivity over its SUBOXONE tablets after the Food and Drug Administration (FDA) gave two drug manufacturers the green light to produce generic versions of the drug.

The RB Pharmaceuticals business (RBP) had filed a 'Citizen's Petition' to the FDA to raise the barrier to generic versions of the product, which is used in the treatment for the chronic diseases of addiction.

RBP had called for more stringent packaging standards and increased educational interventions to help lower the number of children exposed to products that contain buprenorphine - found in RBP's SUBOXONE tablets - which is used to treat opioid dependence.

Reckitt announced on Monday morning that the FDA had denied its petition, saying that existing labelling and safety programmes were "sufficient". As such, the regulator approved two generic versions of the tablet in the US, which accounted for around 5.0% of group profits last year, according to analyst Martin Deboo from Investec.

Meanwhile, analysts at Jefferies estimate that these generics "could enter the market within a month". They said that this would cut around 3.0% off full-year earnings at Reckitt and around 8.0% shed from 2014 earnings.

The broker said: "Whilst the possibility of generic entry has been a well-flagged risk for the Reckitt investment case for some time, we believe that the market had become somewhat complacent of the risks, and indeed that a number of investors had gradually come around to the view that generics would never enter the market.

"On this basis, we would expect the shares to tick down as the market gradually digests the impact of this news over the coming days."

Shares were down 3.01% at 4,380p before the close of trade in London.

Reckitt disappointedThe company said that it is "disappointed" with the decision but will continue to work with the FDA on safety enhancements.

"RBP remains committed to maintaining its own high level standards for safety, including the use of child resistant, unit-dose packaging for its buprenorphine-based opioid dependence treatment products.

"It will therefore carry on with the decision to discontinue the sale of its loose tablet bottles of SUBOXONE in the United States in favour of other effective treatment options that have shown reduced paediatric exposure rates."

Reckitt makes a wide range of household cleaning products such as Cillit Bang and Calgon, but is also responsible for brands such as Nurofen and Strepsils.

Recommended

Share tips of the week – 1 July
Share tips

Share tips of the week – 1 July

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
1 Jul 2022
Bunzl: boring is good for business
Share tips

Bunzl: boring is good for business

Food-service distribution company Bunzl is not a terribly exciting business, but it looks cheap and could be a great investment, says Rupert Hargreave…
30 Jun 2022
Five dividend stocks to beat inflation
Share tips

Five dividend stocks to beat inflation

During periods of high inflation, dividend stocks tend to do better than the wider market. Here, Rupert Hargreaves pick five dividend stocks for incom…
30 Jun 2022
Three Sharia-compliant growth companies
Share tips

Three Sharia-compliant growth companies

Professional investor Scott Klimo of the Saturna Al-Kawthar Global Focused Equity ETF tips three Sharia-compliant stocks.
30 Jun 2022

Most Popular

How to find the best dividend stocks
Income investing

How to find the best dividend stocks

Stocks that pay dividends tend to outperform the market over the long run - as well as providing an income. Here, Rupert Hargreaves explains the best …
28 Jun 2022
Gold has been incredibly boring to own – but that’s no bad thing right now
Gold

Gold has been incredibly boring to own – but that’s no bad thing right now

Stocks, bonds and cryptocurrencies have all seen big falls this year. But gold remains at its one-year average. It may be dull, but it’s doing what it…
29 Jun 2022
What the end of the 1970s bear market can teach today’s investors
Stockmarkets

What the end of the 1970s bear market can teach today’s investors

The 1970s saw the worst bear market Britain has ever seen, with stocks tumbling 70%. Things have changed a lot since then, says Max King. But there ar…
28 Jun 2022